The SELENE study
Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the SELENE study for which she was one of the investigators. This phase 3 study evaluated ibrutinib plus bendamustine-rituximab or R-CHOP in previously treated patients with follicular or marginal zone lymphoma to determine if the addition of ibrutinib would prolong progression-free survival.
With the educational support of:
